CTMX — CytomX Therapeutics Share Price
0.000.00%
Last trade - 00:00- $64.66m
- -$35.96m
- $138.10m
- 32
- 99
- 67
- 73
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.47 | ||
| EV to EBITDA | -1.34 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 71.91% | ||
| Return on Equity | n/a | ||
| Operating Margin | 18.1% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 100.36 | 37.31 | 53.16 | 101.21 | 138.1 | 99.24 | 29.25 | 19.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | -97.61 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
Directors
- Sean McCarthy CHM (54)
- Amy Peterson PRE (54)
- Carlos Campoy CFO (56)
- Lloyd Rowland SVP (64)
- Alison Hannah SVP (59)
- Matthew Young LED (51)
- Alan Ashworth DRC
- Halley Gilbert IND (51)
- Frederick Gluck IND (85)
- Elaine Jones IND (66)
- James Meyers IND (55)
- Mani Mohindru IND (49)
- John Scarlett IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 16th, 2010
- Public Since
- October 8th, 2015
- No. of Shareholders
- 20
- No. of Employees
- 119
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 80,621,293
- Address
- 151 Oyster Point Blvd., Suite 400, SOUTH SAN FRANCISCO, 94080
- Web
- https://cytomx.com/
- Phone
- +1 6505153185
- Auditors
- Ernst & Young LLP
Upcoming Events for CTMX
CytomX Therapeutics Inc Annual Shareholders Meeting
CytomX Therapeutics Inc Annual Shareholders Meeting
Q2 2025 CytomX Therapeutics Inc Earnings Release
Similar to CTMX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the CytomX Therapeutics share price?
As of Today at 20:09 UTC, shares in CytomX Therapeutics are trading at $0.80. This share price information is delayed by 15 minutes.
How has the CytomX Therapeutics share price performed this year?
Shares in CytomX Therapeutics last closed at $0.80 and the price had moved by -82.18% over the past 365 days. In terms of relative price strength the CytomX Therapeutics share price has underperformed the S&P500 Index by -83.93% over the past year.
What are the analyst and broker recommendations for CytomX Therapeutics?
The overall consensus recommendation for CytomX Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the CytomX Therapeutics dividend yield?
CytomX Therapeutics does not currently pay a dividend.
Does CytomX Therapeutics pay a dividend?
CytomX Therapeutics does not currently pay a dividend.
When does CytomX Therapeutics next pay dividends?
CytomX Therapeutics does not currently pay a dividend.
How do I buy CytomX Therapeutics shares?
To buy shares in CytomX Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CytomX Therapeutics?
As of the previous close price of $0.80, shares in CytomX Therapeutics had a market capitalisation of $64.66m.
Where are CytomX Therapeutics shares listed?
Here are the trading details for CytomX Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CTMX
What kind of share is CytomX Therapeutics?
Based on an overall assessment of its quality, value and momentum CytomX Therapeutics is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CytomX Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in CytomX Therapeutics is $4.75. That is 492.27% above the last closing price of $0.80.
Analysts covering CytomX Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $0.01 for the next financial year.
Find out moreWhat is the trend in the CytomX Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CytomX Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -23.27%.
As of the last closing price of $0.80, shares in CytomX Therapeutics were trading -18.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CytomX Therapeutics PE Ratio?
The CytomX Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CytomX Therapeutics?
CytomX Therapeutics' management team is headed by:
- Sean McCarthy - CHM
- Amy Peterson - PRE
- Carlos Campoy - CFO
- Lloyd Rowland - SVP
- Alison Hannah - SVP
- Matthew Young - LED
- Alan Ashworth - DRC
- Halley Gilbert - IND
- Frederick Gluck - IND
- Elaine Jones - IND
- James Meyers - IND
- Mani Mohindru - IND
- John Scarlett - IND